|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||-2.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.62|
CINCINNATI, OH / ACCESSWIRE / October 2, 2018 / Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the ''Company'' or ''Callitas'') an integrated clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that it signed a definitive Patent Technology Assignment Agreement with Ronald J. Thompson, MD to expand its cannabis delivery technology portfolio. The new intellectual property acquired (four separate patent applications) will cover various novel oral and ingestible products including those for orally dissolving immediate cannabis effect, sustained release cannabis effect, and a combination of both. ''Using our clinically-proven delivery technology, pharmaceutical development and intellectual property experience, we have developed and acquired multiple new patent applications that define and protect a continuum of novel advanced cannabis dosing technologies,'' said Callitas CEO, James Thompson.
CINCINNATI, OH / ACCESSWIRE / September 18, 2018 / Callitas Health Inc. (CNSX: LILY, OTCQB: MPHMF, FSE: T3F3), (the "Company" or "Callitas"), an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, today announced that it has been notified by the British Columbia Securities Commission of regulatory deficiencies for the second quarter ended June 30, 2018. A cease trade order was issued for failure to file the second quarter financial statements and report, as well as the management disccussion and analysis prior to August 30, 2018. Callitas has been in contact with the British Columbia Sercurities Commission and is working diligently to file all outstanding documents in order to fully comply with the Commission's filing requirements.
CINCINNATI, OH, Sept. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) announced today with great sadness, that, Gary A. Thompson, Former President and Chief Executive Officer of Callitas Health, died on September 11, 2018, after a long battle with cancer. Board Member, William Rodgers stated, “On behalf of our Board of Directors, management team and employees, we extend our deepest sympathies to the entire Thompson family.
Vancouver, British Columbia--(Newsfile Corp. - August 24, 2018) - Callitas Health Inc. (CSE: LILY) (OTCQB: MPHMF) (FSE: T3F3) has signed a consulting agreement with BFS Innovations and Pure Leaf Group to globally launch the company's patent-pending cannabis delivery technology and proprietary business model.Cannot view this video? Visit:http://www.investmentpitch.com/video/0_pxyaxst3/Callitas-Health-Inc-CSELILY-has-signed-a-consulting-agreement-with-BFS-Innovations-and-Pure-Leaf-GroupInvestmentPitch.com has produced a "video" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Callitas" in the search box. Scott ...
CINCINNATI, OH / ACCESSWIRE / August 17, 2018 / Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the "Company" or "Callitas") today announced that it has signed a consulting agreement with BFS Innovations and Pure Leaf Group to launch Callitas' patent-pending cannabis delivery technology and proprietary business model globally. "This partnership allows Callitas to expand its reach and engage more groups locally and internationally," said James Thompson, President and CEO.
“At LifeStyles, our mission is to spark billions of joyful moments every day, regardless of gender, age, race, religion and sexuality. “We are pleased to extend our business relationship with Lifestyles,” said James Thompson, President and CEO of Callitas Health.
I am going to take a deep dive into Callitas Health Inc’s (DB:T3F3) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...
If you are a shareholder in Callitas Health Inc’s (DB:T3F3), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
When Callitas Health Inc (DB:T3F3) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...
Investors are always looking for growth in small-cap stocks like Callitas Health Inc (DB:T3F3), with a market cap of €6.24M. However, an important fact which most ignore is: how financiallyRead More...